SOURCE: Avisio, Inc.

December 10, 2009 08:30 ET

Avisio Appoints Agenor Mafra-Neto, Ph.D. to the Board of Diagnostic Nano Applications Corporation

RIVERSIDE, CA--(Marketwire - December 10, 2009) - Avisio, Inc. (PINKSHEETS: AVIC) announced today that it has appointed Agenor Mafra-Neto, Ph.D. to Diagnostic Nano Applications Corporation's (DNA) board.

He is the founder, president and CEO of ISCA Technologies, Inc., a developer of environmentally friendly, natural and pheromone-based tools and solutions for agricultural and urban applications. Dr. Mafra-Neto is a leading researcher and the recipient of multiple grants and contracts. He is currently the principal investigator of six active, fully funded, research and development programs -- three awarded by the US Department of Agriculture and three by the National Science Foundation.

He holds both a Bachelor of Science and Master of Science degree in biology from Universidade Estadual de Campinas and a Ph.D. in entomology from the University of Massachusetts. He completed his post doctoral work in 1996 at Iowa State University.

About Avisio, Inc.

Avisio, Inc. is a publicly-traded technology commercialization company with a mission to unlock the value of high-potential assets and transform them into high-value businesses. Avisio plans to create a new majority-owned private subsidiary around each asset and to support each business with experienced management teams, best-of-breed commercialization processes and resources, and access to global capital sources. For more information, please visit www.avisioinc.com

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based largely on expectations and projections about future events and future trends and are subject to numerous assumptions, risks and uncertainties, which change over time. Avisio's actual results could differ materially from those anticipated in forward-looking statements and you should not place any undue reliance on such forward-looking statements.

The forward-looking statements in this news release are made as of the date hereof, and Avisio does not assume any obligation to update, amend or clarify them to reflect events, new information or circumstances occurring after the date hereof.

Contact Information